262 related articles for article (PubMed ID: 8641848)
1. PC-10 as a predictor of prognosis after antigen retrieval in posterior uveal melanoma.
Seregard S; Oskarsson M; Spångberg B
Invest Ophthalmol Vis Sci; 1996 Jun; 37(7):1451-8. PubMed ID: 8641848
[TBL] [Abstract][Full Text] [Related]
2. Prognostic accuracy of the mean of the largest nucleoli, vascular patterns, and PC-10 in posterior uveal melanoma.
Seregard S; Spångberg B; Juul C; Oskarsson M
Ophthalmology; 1998 Mar; 105(3):485-91. PubMed ID: 9499780
[TBL] [Abstract][Full Text] [Related]
3. Human leukocyte antigen class I expression. Marker of poor prognosis in uveal melanoma.
Blom DJ; Luyten GP; Mooy C; Kerkvliet S; Zwinderman AH; Jager MJ
Invest Ophthalmol Vis Sci; 1997 Aug; 38(9):1865-72. PubMed ID: 9286277
[TBL] [Abstract][Full Text] [Related]
4. Comparative analysis of proliferating cell nuclear antigen, bromodeoxyuridine, and mitotic index in uveal melanoma.
Ghazvini S; Kroll S; Char DH; Frigillana H
Invest Ophthalmol Vis Sci; 1995 Dec; 36(13):2762-7. PubMed ID: 7499099
[TBL] [Abstract][Full Text] [Related]
5. Prognostic factors for survival after enucleation for choroidal and ciliary body melanomas.
Isager P; Ehlers N; Overgaard J
Acta Ophthalmol Scand; 2004 Oct; 82(5):517-25. PubMed ID: 15453846
[TBL] [Abstract][Full Text] [Related]
6. No differences in outcome between radical surgical treatment (enucleation) and stereotactic radiosurgery in patients with posterior uveal melanoma.
Furdova A; Slezak P; Chorvath M; Waczulikova I; Sramka M; Kralik G
Neoplasma; 2010; 57(4):377-81. PubMed ID: 20429631
[TBL] [Abstract][Full Text] [Related]
7. Insulin-like growth factor-1 receptor in uveal melanoma: a predictor for metastatic disease and a potential therapeutic target.
All-Ericsson C; Girnita L; Seregard S; Bartolazzi A; Jager MJ; Larsson O
Invest Ophthalmol Vis Sci; 2002 Jan; 43(1):1-8. PubMed ID: 11773005
[TBL] [Abstract][Full Text] [Related]
8. Ruthenium brachytherapy for uveal melanoma, 1979-2003: survival and functional outcomes in the Swedish population.
Bergman L; Nilsson B; Lundell G; Lundell M; Seregard S
Ophthalmology; 2005 May; 112(5):834-40. PubMed ID: 15878063
[TBL] [Abstract][Full Text] [Related]
9. Routes of extraocular extension of uveal melanoma: risk factors and influence on survival probability.
Coupland SE; Campbell I; Damato B
Ophthalmology; 2008 Oct; 115(10):1778-85. PubMed ID: 18554722
[TBL] [Abstract][Full Text] [Related]
10. Ezrin as a prognostic indicator and its relationship to tumor characteristics in uveal malignant melanoma.
Mäkitie T; Carpén O; Vaheri A; Kivelä T
Invest Ophthalmol Vis Sci; 2001 Oct; 42(11):2442-9. PubMed ID: 11581181
[TBL] [Abstract][Full Text] [Related]
11. KI-67 immunopositivity in choroidal and ciliary body melanoma with respect to nucleolar diameter and other prognostic factors.
Al-Jamal RT; Kivelä T
Curr Eye Res; 2006 Jan; 31(1):57-67. PubMed ID: 16421020
[TBL] [Abstract][Full Text] [Related]
12. Iodine brachytherapy as an alternative to enucleation for large uveal melanomas.
Puusaari I; Heikkonen J; Summanen P; Tarkkanen A; Kivelä T
Ophthalmology; 2003 Nov; 110(11):2223-34. PubMed ID: 14597534
[TBL] [Abstract][Full Text] [Related]
13. Expression of PCNA and Ki-67 in posterior uveal melanomas in adults.
Proniewska-Skretek E; Dziecioł J; Zalewska R; Mariak Z
Rocz Akad Med Bialymst; 2004; 49 Suppl 1():79-81. PubMed ID: 15638382
[TBL] [Abstract][Full Text] [Related]
14. Expression of epidermal growth factor receptor: risk factor in uveal melanoma.
Hurks HM; Metzelaar-Blok JA; Barthen ER; Zwinderman AH; De Wolff-Rouendaal D; Keunen JE; Jager MJ
Invest Ophthalmol Vis Sci; 2000 Jul; 41(8):2023-7. PubMed ID: 10892838
[TBL] [Abstract][Full Text] [Related]
15. An immunohistochemical and prognostic analysis of cytokeratin expression in malignant uveal melanoma.
Fuchs U; Kivelä T; Summanen P; Immonen I; Tarkkanen A
Am J Pathol; 1992 Jul; 141(1):169-81. PubMed ID: 1378696
[TBL] [Abstract][Full Text] [Related]
16. [Intratumoral blood pools and prognosis of malignant uveal melanoma treated with enucleation].
Kantelip B; Albuisson E; Bacin F; Bonhomme R
Ophtalmologie; 1989; 3(1):49-52. PubMed ID: 2641072
[TBL] [Abstract][Full Text] [Related]
17. Carcinoembryonic antigen cell adhesion molecule-1 (CEACAM1) in posterior uveal melanoma: correlation with clinical and histological survival markers.
Khatib N; Pe'er J; Ortenberg R; Schachter J; Frenkel S; Markel G; Amer R
Invest Ophthalmol Vis Sci; 2011 Dec; 52(13):9368-72. PubMed ID: 22039239
[TBL] [Abstract][Full Text] [Related]
18. JARID1B protein expression and prognostic implications in uveal melanoma.
Radberger P; Radberger A; Bykov VJ; Seregard S; Economou MA
Invest Ophthalmol Vis Sci; 2012 Jul; 53(8):4442-9. PubMed ID: 22669717
[TBL] [Abstract][Full Text] [Related]
19. Tumor-infiltrating macrophages (CD68(+) cells) and prognosis in malignant uveal melanoma.
Mäkitie T; Summanen P; Tarkkanen A; Kivelä T
Invest Ophthalmol Vis Sci; 2001 Jun; 42(7):1414-21. PubMed ID: 11381040
[TBL] [Abstract][Full Text] [Related]
20. PC-10 immunostaining of proliferating cell nuclear antigen in posterior uveal melanoma. Enucleation versus enucleation postirradiation groups.
Pe'er J; Gnessin H; Shargal Y; Livni N
Ophthalmology; 1994 Jan; 101(1):56-62. PubMed ID: 7905616
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
